林橙莉

Bio: 林橙莉 is an academic researcher. The author has contributed to research in topics: Retrospective cohort study & Vaccination. The author has an hindex of 1, co-authored 2 publications receiving 6 citations.

Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review

Abstract: Influenza is associated with an increased risk of complications, especially in diabetic mellitus patients who are more susceptible to influenza infection. Despite recommendations of the WHO and public health authorities, vaccination uptake in this population remains suboptimal. This systematic review identified 15 studies published between January 2000-March 2017 in PubMed, Embase and Cochrane Library, which provided data on immunogenicity, safety, effectiveness, and/or cost-effectiveness of seasonal influenza vaccination in diabetic patients. Immunogenicity of seasonal influenza vaccination in diabetic patients was generally comparable to that of healthy participants. One month after vaccination of diabetic patients, seroconversion rates and seroprotection ranged from 24.0–58.0% and 29.0–99.0%, respectively. Seasonal influenza vaccination reduced the risk of hospitalization and mortality in diabetic patients, particularly those aged ≥65 years. These review results demonstrate and reinforce the ne...

The Effectiveness of Influenza Vaccination in Different Groups.

Abstract: Annual administration of the seasonal influenza vaccine, especially to persons known to be at elevated risk for developing serious complications, is the focus of current efforts to reduce the impact of influenza. The main factors influencing estimated inactivated influenza vaccine efficacy and effectiveness, the results obtained in different population groups, current vaccination strategies and the possible advantages of new vaccines are discussed. The available evidence suggests that influenza vaccines are less effective in the elderly than in young adults, but vaccination is encouraged by public health institutions due to higher mortality and complications. There is no consensus on universal vaccination of children yet economic studies suggest that yearly paediatric vaccination is cost saving. The benefits of herd immunity generated by paediatric vaccination require further study. Newer vaccines should be more and more-broadly protective, stable, easy to manufacture and administer and highly immunogenic across all population groups.

Influenza Vaccination in Type 2 Diabetes Patients: Coverage Status and Its Determinants in Southwestern Saudi Arabia.

Abstract: Despite the significant role of seasonal influenza vaccination in preventing and minimizing the serious complications of influenza infection in type 2 diabetes mellitus (T2DM) patients, unsatisfactory compliance still exists for vaccination. Study objectives were to explore the vaccination status and determinants in T2DM patients in southwestern Saudi Arabia. A cross-sectional study on a representative sample of T2DM patients in Abha city, southwestern Saudi Arabia, was conducted. Data for sociodemographic characteristics, clinical criteria, vaccination status, vaccination motivators and barriers and seasonal influenza knowledge were collected. Out of 353 T2DM patients included in the study, seasonal influenza vaccination coverage was 61% in year 2017. A significant factors associated with non-vaccination were; poor influenza and its vaccine knowledge (OR = 4.31, 95% CI: 2.73–6.80), illiteracy (OR = 1.93, 95% CI: 1.11–3.37), and more than 10 years disease duration (OR = 2.07, 95% CI: 1.11–3.87). Presence of family history of DM and ischemic heart comorbidity minimized the possibility of non-vaccination (OR = 0.54 and 0.28 respectively). Healthcare givers’ advice was the most reported vaccination motivator (84.7%) while; fear of vaccine side effects was the most stated barrier (73%). In conclusion, influenza vaccination rate among T2DM in the present study is less than the recommended level. Continuous primary health care center-based educational programs should be implemented to aware and encourage influenza vaccination among T2DM patients.

Hintergrundpapier der STIKO: Evaluation der bestehenden Influenzaimpfempfehlung für Indikationsgruppen und für Senioren (Standardimpfung ab 60 Jahren)

Abstract: Influenzaviren gehören zu den Orthomyxoviren und werden in die Typen A, B und C eingeteilt, wobei für Menschen nur die Influenza-Aund -B-Viren medizinisch relevant sind. Eine Einteilung in weitere Subtypen erfolgt bei den Influenza-B-Viren in zwei genetisch unterschiedliche Linien (die Victoriaund die Yamagata-Linie) und bei den InfluenzaA-Viren anhand der Oberflächenproteine Hämagglutinin (HA) und Neuraminidase (NA), von denen mittlerweile 18 HAund 11 NA-Typen identifiziert wurden [1]. In den vergangenen Jahrzehnten zirkulierten v. a. die Influenza-A-Viren H3N2 und H1N1 sowie Influenza-B-Viren der Victoriaund die Yamagata-Linie [2]. Die genaue (englische) Bezeichnung der Influenzaviren setzt sich zusammen aus dem Influenzatyp (A oder B), dem ursprünglichen Wirt des Subtypen (z. B. swine, chicken; bei humanem Ursprung wird diese Namenskomponente weggelassen), dem Ort der ersten Isolierung (z. B. California, Brisbane), einer Nummer des Isolats, dem Jahr der Isolation (z. B. 57 für 1957 oder 2009) und bei Influenza-A-Viren die Bezeichnung des HAund des NA-Typs (z. B. H1N1 oder H3N2) [3]. So wurde das während der Pandemie zirkulierende Virus mit der Bezeichnung A/California/7/2009 (H1N1) versehen. Häufig wird nur die Kurzbezeichnung der Influenzaviren angegeben, also Influenza B in Kombination mit der entsprechenden Linie (z. B. Influenza B/Yamagata) bzw. bei den AViren der entsprechende Subtyp (z. B. A/ H3N2). Eine Besonderheit der Influenzaviren ist ihre große genetische Variabilität. Durch ständig stattfindende Mutationen verändern sich die RNA-Viren kontinuierlich, wobei die Mutationsrate beim Influenza-A-Virus höher ist als beim Influenza-B-Virus [4]. Durch Punktmutationen verursachte genetische Veränderungen werden als Antigendrift bezeichnet. Größere, durch Reassortierung bedingte Veränderungen bezeichnet man als Antigenshift, die zur Entstehung neuer pandemischer Influenzaviren führen können. Grundlage der Reassortierung bei Influenza-A-Viren ist auch die Tatsache, dass Influenza-A-Viren viele extrahumane Wirte infizieren können. Bereits durch Antigendrifts kann sich das Influenzavirus derart verändern, dass Antikörper, die gegen frühere Varianten des Influenzasubtyps gebildet wurden, keinen oder nur einen partiellen Schutz gegen eine Infektion durch die veränderte Variante bieten [5]. Dadurch fehlt nach durchgemachter Infektion oder nach Impfung eine langanhaltende Immunität, was wiederum zum Auftreten jährlicher Influenzawellen führt. Bei einem Antigenshift können größere genetische Veränderungen durch Austausch von Gensegmenten (Reassortierung) zu einer InfluenzaCornelius Remschmidt · Thomas Harder · Ole Wichmann · Edeltraut Garbe · Thomas Ledig · Martin Terhardt · Sabine Wicker · Fred Zepp · Thomas Mertens 1 Fachgebiet Impfprävention, Robert Koch-Institut, Berlin, Deutschland 2 Klinische Epidemiologie, Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH, Bremen, Deutschland

Association between Trimetazidine and Parkinsonism: A Population-Based Study.

Abstract: Background: The prevalence of drug-induced parkinsonism (DIP) has been reported with the use of trimetazidine (TMZ), an antianginal medication available in Asian and European countries. Very few studies have evaluated the association between DIP and TMZ use, and studies using population-based data from national databases are lacking. Objectives: To investigate the association between DIP and use of TMZ in patients with angina using data from a national healthcare claims database and to determine the predictive factors of DIP in TMZ use. Methods: A cross-sectional study was conducted on patients aged 40 years or more diagnosed with angina, using the Korean National Healthcare claims 2014 database. The association between TMZ use and DIP was evaluated using multivariate logistic regression analysis, adjusting for confounders, including age; sex; insurance type; comorbidities; and concurrent medications known to be commonly associated with DIP, such as typical and atypical antipsychotics. Results: Of the patients included in the study, 19% were prescribed TMZ. In addition, 2.5% of TMZ users had preexisting extrapyramidal and movement disorders. TMZ use was found to be a significant predictor of a new diagnosis of parkinsonism (adjusted OR [aOR] 1.39; 95% CI 1.06–1.81; p = 0.016). Age ≥65 years (aOR 2.07; 95% CI 1.13– 3.74; p = 0.017) and stroke as comorbid disease (aOR 3.23; 95% CI 1.87–5.61; p < 0.001) were also significantly associated with a new diagnosis of parkinsonism in TMZ users. Conclusions: Treatment with TMZ was a statistically significant predictor of a new diagnosis of parkinsonism. Efforts should focus on close monitoring of, and education on, TMZ use in relation to DIP in all patients who are prescribed TMZ, including those with preexisting extrapyramidal and movement disorders.